Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by Dwizellon Oct 04, 2019 4:04pm

109 Views

Post# 30198175

RE:oncology

canadapiet wrote: 1.7 Million Dollars Grant Towards Development of Theratechnologies' Targeted Oncology
Read more at https://stockhouse.com/news/press-releases/2019/10/04/1-7-million-dollars-grant-towards-development-of-theratechnologies-targeted#bh2whpOEHjG9Vl3f.99

And no reaction???? Except going down........:-(

Do not understand!!!!!

It's a good thing. It will reduce our overall R&D costs for oncology by 1.7million, one time. So it worth 2 cents per action to refelct the saving. Note really more.

Bullboard Posts

Changing Europe’s dependency on HREE from China